The long-awaited Phase II clinical trial by the Usona Institute was finally published in August. The results are positive and on par with earlier trials. The trial tested 25 mg of psilocybin in combination with talk therapy. The key finding of the 104-person trial is a reduction of 12 points on the MADRS scale (a common measure of depression scores) over placebo (niacin). Interestingly…


Previous articlePT440 – Coming Back to Stillness, Microdosing and Adaptogens, and What We Can Learn From Autism
Next articleBetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001